Traders should monitor upcoming catalysts: PDUFA decision for brepocitinib in dermatomyositis (Q3 2026), topline data in NIU and CS (H2 2026), and strategic updates on batoclimab post-failure. The LPP program adds optionality but is earlier in development. Downside risk from TED failure partially offset by progress in other high-potential autoimmune programs.
Price Chart
Executive Summary
Roivant announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare scarring hair loss condition with no approved therapies, while reporting that Immunovant's Phase 3 trials of batoclimab in thyroid eye disease (TED) failed to meet their primary endpoint. The company continues to advance other late-stage programs, including brepocitinib for dermatomyositis, with a PDUFA date in Q3 2026.
Key Facts
- Roivant initiated a seamless Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), enrolling first patients in March 2026.
- No FDA-approved therapies currently exist for LPP, affecting ~100,000 adults in the U.S.
- Immunovant’s two Phase 3 studies of batoclimab in thyroid eye disease (TED) failed to meet the primary endpoint of ≥2mm proptosis reduction at Week 24.
- Safety data for batoclimab were consistent with prior findings; deeper IgG suppression during high-dose phase showed greater proptosis improvement.
- FDA granted Priority Review for brepocitinib’s NDA in dermatomyositis with a PDUFA date in Q3 2026.
- Topline data expected in 2026 for non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 in Graves’ disease to report data in 2027.
Financial Impact
Potential long-term revenue upside from brepocitinib expansion into LPP and upcoming dermatomyositis launch, offset by failure of batoclimab in TED which may reduce near-term commercial expectations.
Risk Factors
- Batoclimab’s failure in TED reduces near-term commercial potential and may lead to program discontinuation.
- Brepocitinib remains unproven in LPP despite mechanistic rationale; clinical success not guaranteed.
- High valuation ($19.9B market cap) makes Roivant sensitive to clinical setbacks and dependent on near-term execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267157 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $36.80 | awaiting T+20 | — | $36.05 (−2.04%) |
Oct 5, 2026 21d ago | Insider Cluster | $35.53 | awaiting T+20 | — | $36.05 (−1.46%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 1, 2026 7w ago | Insider Cluster | $34.18 $36.57 | ▲ +6.99% | ▲ +7.32% | $36.05 (+5.47%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 26, 2026 8w ago | Press Release | $36.75 $38.99 | ▲ +6.10% | ▲ +4.89% | $36.05 (−1.90%) |
Aug 6, 2026 11w ago | 8-K | $35.12 $34.41 | ▼ −2.02% | ▼ −2.62% | $36.05 (+2.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers